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FPIN's Clinical Inquiries 
A1C Testing in the Diagnosis of Diabetes Mellitus 
Clinical Question 
Can A1C measurements be used to diagnose diabetes mellitus? 
Evidence-Based Answer 
A1C testing is highly specific compared with a two-hour oral glucose tolerance test (OGTT) or a 
fasting plasma glucose test. However, because A1C testing is not sensitive enough to rule out 
diabetes if levels are normal, the test should not be used for diagnosing diabetes.1 (Strength of 
recommendation: C). 
Evidence Summary 
The accuracy of A1C testing for the diagnosis of diabetes was first evaluated using pre-1997 
World Health Organization (WHO) criteria for a diabetes diagnosis (i.e., OGTT result more than 
140 mg per dL [7.8 mmol per L] fasting or more than 200 mg per dL [11.1 mmol per L] at two 
hours). A meta-analysis1 (including 10 studies that evaluated A1C levels of 8,984 patients) that 
used a cutoff (i.e., upper limit of normal) A1C level of 6.3 percent (two standard deviations [SD] 
above the mean) showed that A1C testing was 66 percent sensitive and 98 percent specific for 
diagnosing diabetes (Table 11,2). Based on an assumed diabetes prevalence rate of 6 percent in 
the general population (i.e., persons without known diabetes), 63 percent of patients with an A1C 
level more than 6.3 percent would have diabetes (positive predictive value [PPV] = 63 percent). 
table 1 
Accuracy of AIC Testing for Diabetes 
Cutoff A1C level (%) (standard 
deviations above the mean) 
Sensitivity 
(%) 
Specificity 
(%) 
Positive predictive 
value* 
Peters, et al., 19961 
6.3 (2) 66 98 63 
6.8 (3) 48 100 90 
7.3 (4) 36 100 97 
Rohlfing, et al., 20002 
5.6 (1) 83.4 84.4 25 
6.1 (2) 63.2 97.4 57 
6.5 (3) 42.8 99.6 86 
7.0 (4) 28.3 99.9 94 
 
*-Positive predictive values were calculated using an assumed diabetes prevalence 
rate of 6 percent in the general population (i.e., persons without known diabetes). 
Information from references 1 and 2. 
A subsequent study2 that used current WHO criteria for defining diabetes (i.e., fasting plasma 
glucose of 126 mg per dL [7.0 mmol per L] or more) showed similar results. This cross-sectional 
study3 of 6,559 patients that used a cutoff A1C level of 6.1 percent and assumed a diabetes 
prevalence rate of 6 percent showed A1C testing was 63.2 percent sensitive and 97.4 percent 
specific for diagnosing diabetes (PPV = 57 percent). A subgroup analysis2 of these results 
showed that the sensitivity of A1C testing was considerably higher in Mexican Americans and 
blacks (83.6 and 75.8 percent, respectively) compared with non-Hispanic whites (58.6 percent). 
The reason for these differences is unclear; however, these results may suggest physiologic 
variations among ethnic groups. If this is verified in future, larger studies, A1C testing may have 
a role in diagnosing diabetes in some patient populations. 
Recommendations from Others 
The American Diabetes Association (ADA) does not recommend A1C testing for the diagnosis 
of diabetes.3 Instead, it recommends fasting plasma glucose testing (126 mg per dL or more is 
diagnostic) as the test of choice because it is easier and faster to perform and less expensive than 
other screening tests. Table 23 includes the ADA criteria for diagnosing diabetes. Although the 
ADA guideline points out that A1C testing historically had not been standardized among 
laboratories, the test has become widely standardized in the United States since the guideline's 
publication.4 The European Diabetes Policy Group guideline5 also does not recommend A1C 
testing for diagnosing diabetes and recommends confirming the diagnosis in persons with 
elevated A1C levels using fasting plasma glucose testing (126 mg per dL or more is diagnostic). 
table 2 
American Diabetes Association Criteria for the Diagnosis of Diabetes Mellitus* 
Diabetes mellitus can be diagnosed if at least one of the following clinical findings is 
present: 
Symptoms of diabetes (e.g., polyuria, polydipsia, unexplained weight loss) plus 
casual† plasma glucose ≥ 200 mg per dL (11.1 mmol per L) 
Fasting‡ plasma glucose ≥ 126 mg per dL (7.0 mmol per L) 
Two-hour postload glucose ≥ 200 mg per dL according to an oral glucose tolerance 
test§ 
 
*-In the absence of unequivocal hyperglycemia, these criteria should be confirmed by 
repeat testing on another day. 
†-A casual glucose measurement is determined any time of day without regard to 
time since last meal. 
‡-Fasting is defined as no caloric intake for at least eight hours. 
§-Oral glucose tolerance tests are not recommended for routine clinical use and 
should be performed as described by the World Health Organization (i.e., using a 
glucose load containing the equivalent of 75 g of anhydrous glucose dissolved in 
water). 
Adapted with permission from Report of the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus. Diabetes Care 2003;26(suppl 1):S12. 
Clinical Commentary 
Although most of the literature on diabetes includes the two-hour OGTT as the standard test for 
diagnosing diabetes, in daily clinical practice, this approach is not always feasible. Fasting 
plasma glucose testing has been shown to have slightly lower sensitivity for predicting 
microvascular complications from diabetes compared with the two-hour OGTT, but it is easier to 
perform compared with the two-hour OGTT. Therefore, fasting plasma glucose testing is widely 
used as the preferred diagnostic test. 
Some physicians believe that because glycemic treatment for diabetes is not aggressively 
initiated until A1C levels are 7 percent or more, A1C testing can be used for diagnosis despite its 
low sensitivity. However, there are other important interventions (e.g., improving blood pressure, 
lowering low-density lipoprotein cholesterol, aspirin therapy, influenza vaccination) that are 
recommended for patients with diabetes, even those with A1C levels less than 7 percent.6 
Therefore, fasting plasma glucose testing remains the preferred diagnostic test for diabetes. 
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